UNSPSC 51351509: Medroxyprogesterone

This classification denotes a therapeutic progestin with the molecular formula C22H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HSU1C9YRES, chemically known as 17-hydroxy-6alpha-methyl-pregn-4-ene-3,20-dione but generally known as medroxyprogesterone, which bears US NIH Compound Identifier 10631. European Medicines Agency schedules Medroxyprogesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08699MIG.

UNSPSC 51351509 Medroxyprogesterone is a Commodity code covering pharmaceutical active ingredients and finished pharmaceutical products supplied through state and local procurement channels. State and local governments buy generic pharmaceuticals and over-the-counter products under this code through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and distribute through authorized pharmaceutical wholesalers. The work involves manufacturers or distributors supplying products with specific National Drug Codes, managing pricing formats, maintaining regulatory compliance with cGMP and Drug Supply Chain Security Act (DSCSA) requirements, and establishing relationships with authorized wholesalers that hold chargeback systems. Issuing bodies include state health and human services departments, county public health offices, and allied state purchasing authorities that participate in multi-state cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent vehicle for this commodity at the state and local level.

Recent activity clusters in the Upper Midwest and Pacific Northwest, with MMCAP's January 2026 RFP serving Oregon and other participating states. The most recent opportunity is the Minnesota Department of Administration's MMCAP RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, which requires vendors to supply identified pharmaceutical products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with awarded contracts effective July 1, 2026. The RFP weights price competitiveness at 75 percent, with supporting evaluation criteria for fixed pricing (10 percent), compliance with administrative data format (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and must certify current Good Manufacturing Practices compliance and Drug Supply Chain Security Act adherence. Contract terms run two years for new responders with optional extensions, and MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and patient safety.